BMC Complementary Medicine and Therapies

Table 6 P values for change in eGFR levels within the groups (from baseline to the end of the treatment period) and between the groups

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Group	4 weeks	8 weeks	12 weeks	16 weeks	20 weeks	24 weeks
A	ns	ns	p ≤ 0.005	p ≤ 0.005	p ≤ 0.0001	p ≤ 0.0001
B	ns	ns	p ≤ 0.005	p ≤ 0.0001	p ≤ 0.0001	p ≤ 0.005
C	ns	p ≤ 0.05	p ≤ 0.01	p ≤ 0.005	p ≤ 0.0001	p ≤ 0.0001
A vs B	ns	ns	ns	ns	p ≤ 0.05	p ≤ 0.01
A vs C	ns	ns	ns	ns	ns	ns
C vs B	ns	ns	ns	ns	p ≤ 0.05	p ≤ 0.01

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com